newsfilter
← Latest News
GlobeNewswire·

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Full-year 2025 net product revenues of $689 million SYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 millionEMPAVELI® (pegcetacoplan) full year 2025 net product revenue of $102